UCSD Profiles
search, discover, network
Powered by Altman Clinical and
Translational Research Institute
Search
About
Help / Contact Us
Sign in
to edit your profile (add interests, mentoring, photo, etc.)
Menu
Find People
Find Everything
About This Site
Login to Profiles
William Sandborn
Title
Adjunct Professor
School
University of California, San Diego
Department
Surgery
Address
9500 Gilman Drive #0956
CA La Jolla 92093
Phone
858-657-5331
vCard
Download vCard
Biography
Education and Training
Fellowship
1993
Mayo Clinic
Intern/Residency
1990
Loma Linda Univ Medical Center
MD
1987
Loma Linda University
BA
1983
Southern College
ORNG Applications
Websites
Bibliographic
Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can
login
to make corrections and additions, or
contact us for help
.
List All
|
Timeline
Publications by year:
View visualization as text
Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR,
Sandborn W
, Feagan BG, Jairath V. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 Mar 26. PMID: 29596987.
View in:
PubMed
Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G,
Sandborn W
, Feagan BG. Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2018 Mar 16. PMID: 29566131.
View in:
PubMed
Duijvestein M, Battat R, Casteele NV, D'Haens GR,
Sandborn W
, Khanna R, Jairath V, Feagan BG. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Feb 06. PMID: 29411220.
View in:
PubMed
Singh S, George J, Boland BS, Vande Casteele N,
Sandborn W
. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 Jan 23. PMID: 29370397.
View in:
PubMed
Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G,
Sandborn W
. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2017 Nov 21. PMID: 29159893.
View in:
PubMed
Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A,
Sandborn W
, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N. Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. Clin Transl Gastroenterol. 2017 Nov 02; 8(11):e126. PMID: 29095427.
View in:
PubMed
D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A,
Sandborn W
, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating ß7+ T Cells in Crohn's Disease: Report of the TOSCA Study: MADCAM-1Antibody and CNS Immune Surveillance. J Crohns Colitis. 2017 Sep 16. PMID: 28961770.
View in:
PubMed
Deepak P,
Sandborn W
. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am. 2017 Sep; 46(3):603-626. PMID: 28838418.
View in:
PubMed
Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G,
Sandborn W
, Danese S, Jairath V, Feagan BG. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients? J Crohns Colitis. 2017 Aug 25. PMID: 28961959.
View in:
PubMed
Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G,
Sandborn W
, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2017 Aug 24. PMID: 28843356.
View in:
PubMed
Sandborn W
, Su C, Panes J. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 08 03; 377(5):496-7. PMID: 28767341.
View in:
PubMed
Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M,
Sandborn W
, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929. PMID: 28333288.
View in:
PubMed
Rubin DT, Cohen RD,
Sandborn W
, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791. PMID: 28333362.
View in:
PubMed
Sandborn W
, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 Jul; 23(7):1047-1056. PMID: 28410341.
View in:
PubMed
Sandborn W
, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. Eldelumab [anti-interferon-?-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis. 2017 Jul 01; 11(7):811-819. PMID: 28333187.
View in:
PubMed
Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, Shackelton LM, Vandervoort MK, Khanna R, Santillan C, Rimola J, Hindryckx P, Nio CY,
Sandborn W
, D'Haens G, Feagan BG, Jairath V, Stoker J. The development of a magnetic resonance imaging index for fistulising Crohn's disease. Aliment Pharmacol Ther. 2017 Jun 27. PMID: 28653753.
View in:
PubMed
Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L,
Sandborn W
. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2017 Jun 16. PMID: 28625817.
View in:
PubMed
Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG,
Sandborn W
, Feagan BG, Jairath V. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open. 2017 Jun 09; 7(6):e016146. PMID: 28601837.
View in:
PubMed
D'Haens GR,
Sandborn W
, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 Aug; 46(3):292-302. PMID: 28568974.
View in:
PubMed
Vermeire S,
Sandborn W
, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Jul 08; 390(10090):135-144. PMID: 28527704.
View in:
PubMed
Khanna R, Zou G, Stitt L, Feagan BG,
Sandborn W
, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Jun; 112(6):975. PMID: 28417993.
View in:
PubMed
Feagan BG,
Sandborn W
, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017 Apr 29; 389(10080):1699-1709. PMID: 28411872.
View in:
PubMed
Vermeire S, Loftus EV, Colombel JF, Feagan BG,
Sandborn W
, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424. PMID: 27683798.
View in:
PubMed
Loftus EV, Colombel JF, Feagan BG, Vermeire S,
Sandborn W
, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411. PMID: 27683800.
View in:
PubMed
Reinisch W, Colombel JF, D'Haens G,
Sandborn W
, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis. 2017 Apr 01; 11(4):425-434. PMID: 27815351.
View in:
PubMed
Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B,
Sandborn W
. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 Mar 28. PMID: 28353055.
View in:
PubMed
Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B,
Sandborn W
, Peyrin-Biroulet L. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 Apr; 45(8):1058-1072. PMID: 28247573.
View in:
PubMed
Peyrin-Biroulet L, Lopez A,
Sandborn W
. Head-to-head Comparative Studies: Challenges and Opportunities? J Crohns Colitis. 2017 Mar 01; 11(suppl_2):S567-S575. PMID: 27660343.
View in:
PubMed
Panés J,
Sandborn W
, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun; 66(6):1049-1059. PMID: 28209624.
View in:
PubMed
Jairath V, Zou G, Parker CE, MacDonald JK, Mosli MH, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Kherad O, Koutsoumpas A, Minas E, Restellini S, Samaan MA, Khanna R, Levesque BG, D'Haens G,
Sandborn W
, Feagan BG. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Aliment Pharmacol Ther. 2017 Apr; 45(8):1021-1042. PMID: 28164348.
View in:
PubMed
Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG,
Sandborn W
, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 Mar; 45(5):617-630. PMID: 28074618.
View in:
PubMed
Khanna R, Zou G, Stitt L, Feagan BG,
Sandborn W
, Rutgeerts P, McDonald JW, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Jan 10. PMID: 28071654.
View in:
PubMed
Sands BE,
Sandborn W
, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2017 Jan; 23(1):97-106. PMID: 27930408.
View in:
PubMed
Cotter TG, Gathaiya N, Catania J, Loftus EV, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR,
Sandborn W
, Limper AH, Pardi DS. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2017 Jun; 15(6):850-856. PMID: 28013116.
View in:
PubMed
Cotter TG, Binder M, Loftus EV, Abboud R, McNally MA, Smyrk TC, Tremaine WJ,
Sandborn W
, Pardi DS. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2016 Dec 13. PMID: 27965284.
View in:
PubMed
Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S,
Sandborn W
, Singh S. Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017 Feb; 45(3):381-390. PMID: 27928830.
View in:
PubMed
Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S,
Sandborn W
, Singh S. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 May; 15(5):665-674.e5. PMID: 27916678.
View in:
PubMed
Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S,
Sandborn W
. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 Feb; 14(2):110-121. PMID: 27899815.
View in:
PubMed
Feagan BG,
Sandborn W
, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. PMID: 27959607.
View in:
PubMed
Colombel JF, Jharap B,
Sandborn W
, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2016 Nov 7. PMID: 27883215.
View in:
PubMed
Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang CM, Parker C, Khanna R, Shackelton LM, D'Haens G,
Sandborn W
, Feagan BG, Lebwohl B, Leffler DA, Jairath V. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2016 Oct 31. PMID: 27799282.
View in:
PubMed
Arulanandan A, Dulai PS, Singh S,
Sandborn W
, Kalmaz D. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. PMID: 27833391.
View in:
PubMed
Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S,
Sandborn W
, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. Gut. 2016 Oct 25. PMID: 27780886.
View in:
PubMed
Abraham C, Dulai PS, Vermeire S,
Sandborn W
. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 Feb; 152(2):374-388.e4. PMID: 27780712.
View in:
PubMed
Osterman MT,
Sandborn W
, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 Dec; 111(12):1806-1815. PMID: 27670599.
View in:
PubMed
Dulai PS,
Sandborn W
, Gupta S. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. PMID: 27679553.
View in:
PubMed
Dulai PS,
Sandborn W
. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. PMID: 27461274.
View in:
PubMed
Sandborn W
, Feagan BG. Ozanimod Treatment for Ulcerative Colitis. N Engl J Med. 2016 Aug 25; 375(8):e17. PMID: 27557326.
View in:
PubMed
Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J,
Sandborn W
. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 Dec; 32(12):1937-1941. PMID: 27494777.
View in:
PubMed
Khanna R, Nelson SA, Feagan BG, D'Haens G,
Sandborn W
, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016 Aug 08; (8):CD010642. PMID: 27501379.
View in:
PubMed
Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvenstein M, Rimola J, Panes J, D'Haens G,
Sandborn W
, Feagan BG. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2017 Feb; 11(2):246-255. PMID: 27487793.
View in:
PubMed
Lee SD, Rubin DT,
Sandborn W
, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 Aug; 22(8):1870-80. PMID: 27400222; PMCID: PMC4949014.
View in:
PubMed
,
PubMed Central
Bosworth BP,
Sandborn W
, Rubin DT, Harper JR. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 Aug; 22(8):1881-6. PMID: 27416045; PMCID: PMC4949012.
View in:
PubMed
,
PubMed Central
Sandborn W
, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):e121-2. PMID: 27464592.
View in:
PubMed
Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P,
Sandborn W
. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017 Jan; 11(1):35-46. PMID: 27440869.
View in:
PubMed
Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim YI, Grover SC, McDonald JW, Shackelton LM, Khanna R, D'Haens G,
Sandborn W
, Feagan BG, Levesque BG. Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. J Crohns Colitis. 2016 Sep; 10(9):1006-14. PMID: 27385400.
View in:
PubMed
Sandborn W
. The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7):438-41. PMID: 27489526; PMCID: PMC4969780.
View in:
PubMed
,
PubMed Central
Khanna R, Chande N, Vermeire S,
Sandborn W
, Parker CE, Feagan BG. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 Jul; 22(7):1737-43. PMID: 27306074.
View in:
PubMed
Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV,
Sandborn W
, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 Aug; 111(8):1147-55. PMID: 27296941.
View in:
PubMed
Sandborn W
, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 Jul; 44(2):157-69. PMID: 27218676.
View in:
PubMed
Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M,
Sandborn W
, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):1302-9. PMID: 27189916.
View in:
PubMed
Sandborn W
, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. PMID: 27144850.
View in:
PubMed
Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR,
Sandborn W
, Loftus EV. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 Oct; 14(10):1439-44. PMID: 27155552.
View in:
PubMed
Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L,
Sandborn W
, Harismendy O, Gupta S. Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 May; 111(5):746-8. PMID: 27151126.
View in:
PubMed
Gibson PR, Feagan BG,
Sandborn W
, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016 Apr 28; 7:e168. PMID: 27124701; PMCID: PMC4855165.
View in:
PubMed
,
PubMed Central
Dulai PS, Singh S, Casteele NV, Boland BS,
Sandborn W
. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. PMID: 26835982.
View in:
PubMed
Sandborn W
, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 Jul; 32(7):1233-41. PMID: 26986449.
View in:
PubMed
Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG,
Sandborn W
, D'Haens G, Feagan BG. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 05; 150(5):1056-1060. PMID: 27018491.
View in:
PubMed
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W,
Sandborn W
, Sorrentino D, Rutgeerts P. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. PMID: 26946343.
View in:
PubMed
Jharap B, Colombel JF,
Sandborn W
. Reply. Gastroenterology. 2016 Apr; 150(4):1039. PMID: 26926449.
View in:
PubMed
Colombel JF, Sands BE, Rutgeerts P,
Sandborn W
, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016 Feb 18. PMID: 26893500.
View in:
PubMed
D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB,
Sandborn W
. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. PMID: 26850690.
View in:
PubMed
Ley K, Rivera-Nieves J,
Sandborn W
, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016 Mar; 15(3):173-83. PMID: 26822833; PMCID: PMC4890615.
View in:
PubMed
,
PubMed Central
Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG,
Sandborn W
, Feagan BG. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. PMID: 26746169; PMCID: PMC4957452 [Available on 05/01/17].
View in:
PubMed
,
PubMed Central
Sandborn W
, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016 Apr; 10(4):418-28. PMID: 26721935; PMCID: PMC4946756 [Available on 04/01/17].
View in:
PubMed
,
PubMed Central
Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M,
Sandborn W
, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 Apr; 66(4):588-596. PMID: 26646934.
View in:
PubMed
Reiss M,
Sandborn W
. The Role of Psychosocial Care in Adapting to Health Care Reform. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2219-24. PMID: 26589873.
View in:
PubMed
Chande N, Marshall JK, Seow CH,
Sandborn W
, Parker CE, Nelson S, Feagan BG. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflamm Bowel Dis. 2015 Dec; 21(12):2948-57. PMID: 26540276.
View in:
PubMed
Singh S, Stroud AM, Holubar SD,
Sandborn W
, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015 Nov 23; (11):CD001176. PMID: 26593456; PMCID: PMC4917283.
View in:
PubMed
,
PubMed Central
Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL,
Sandborn W
, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. Aliment Pharmacol Ther. 2016 Jan; 43(1):61-72. PMID: 26548868.
View in:
PubMed
Boland BS, Dulai PS, Chang M,
Sandborn W
, Levesque BG. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. PMID: 26618431.
View in:
PubMed
Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I,
Sandborn W
, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. Association Between Response to Etrolizumab and Expression of Integrin aE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):477-87.e9. PMID: 26522261.
View in:
PubMed
Mosli MH, Feagan BG, Zou G,
Sandborn W
, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. Development and validation of a histological index for UC. Gut. 2017 Jan; 66(1):50-58. PMID: 26475633.
View in:
PubMed
Gottlieb K, Travis S, Feagan B, Hussain F,
Sandborn W
, Rutgeerts P. Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis. 2015 Oct; 21(10):2475-82. PMID: 26086596.
View in:
PubMed
Feagan BG,
Sandborn W
, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther. 2015 Nov; 42(10):1170-81. PMID: 26400458.
View in:
PubMed
Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G,
Sandborn W
, Feagan BG, Levesque BG. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015 Nov; 42(10):1200-10. PMID: 26388424.
View in:
PubMed
Rubin DT,
Sandborn W
, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17. PMID: 26386854; PMCID: PMC4621699.
View in:
PubMed
,
PubMed Central
Sandborn W
, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016 Jan; 150(1):96-102. PMID: 26376350.
View in:
PubMed
Vuitton L, Marteau P,
Sandborn W
, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016 Sep; 65(9):1447-55. PMID: 26353983.
View in:
PubMed
Jharap B,
Sandborn W
, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015 Nov; 42(9):1082-92. PMID: 26381802.
View in:
PubMed
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D,
Sandborn W
, Donner A, Vandervoort MK, Morris JC, Feagan BG. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 07; 386(10006):1825-34. PMID: 26342731.
View in:
PubMed
Peyrin-Biroulet L,
Sandborn W
, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. PMID: 26303131.
View in:
PubMed
Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL,
Sandborn W
, Loftus EV. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Aliment Pharmacol Ther. 2015 Oct; 42(7):783-92. PMID: 26264359.
View in:
PubMed
Sandborn W
, Bouguen G. Reply: To PMID 24036054. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2382. PMID: 26247165.
View in:
PubMed
Rutgeerts P, Reinisch W, Colombel JF,
Sandborn W
, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan; 83(1):188-97.e1-3. PMID: 26234693.
View in:
PubMed
Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR,
Sandborn W
. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015 Sep; 42(5):504-14. PMID: 26119226; PMCID: PMC4755132.
View in:
PubMed
,
PubMed Central
Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R,
Sandborn W
. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep; 9(9):738-46. PMID: 26094251; PMCID: PMC4736820.
View in:
PubMed
,
PubMed Central
Vande Casteele N,
Sandborn W
. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. PMID: 26077557.
View in:
PubMed
Peyrin-Biroulet L, Panés J,
Sandborn W
, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. PMID: 26071941.
View in:
PubMed
Sandborn W
, Melmed GY, McGovern DP, Loftus EV, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug; 42(3):330-42. PMID: 26031921.
View in:
PubMed
Panaccione R,
Sandborn W
, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. PMID: 25989338; PMCID: PMC4450894.
View in:
PubMed
,
PubMed Central
Vaughn BP,
Sandborn W
, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. PMID: 25590953; PMCID: PMC4437804.
View in:
PubMed
,
PubMed Central
Dulai PS, Levesque BG, Feagan BG, D'Haens G,
Sandborn W
. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. PMID: 26005012.
View in:
PubMed
Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A,
Sandborn W
, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul; 42(2):188-202. PMID: 25996351.
View in:
PubMed
Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N,
Sandborn W
, Feagan BG. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6):802-19; quiz 820. PMID: 25964225.
View in:
PubMed
Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA,
Sandborn W
. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. PMID: 25956538; PMCID: PMC4584567.
View in:
PubMed
,
PubMed Central
Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG,
Sandborn W
, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016 Jul; 65(7):1119-25. PMID: 25935574.
View in:
PubMed
Sandborn W
. New Targets for Small Molecules in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 May; 11(5):338-40. PMID: 27482177; PMCID: PMC4962684.
View in:
PubMed
,
PubMed Central
Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W,
Sandborn W
, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. J Crohns Colitis. 2015 Aug; 9(8):601-6. PMID: 25908718.
View in:
PubMed
Wade JR, Parker G, Kosutic G, Feagen BG,
Sandborn W
, Laveille C, Oliver R. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015 Aug; 55(8):866-74. PMID: 25735646.
View in:
PubMed
Reinhard A,
Sandborn W
, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L. Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Rev Clin Immunol. 2015 May; 11(5):637-57. PMID: 25837708.
View in:
PubMed
Dulai PS, Mosli M, Khanna R, Levesque BG,
Sandborn W
, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. PMID: 25884529.
View in:
PubMed
Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ,
Sandborn W
. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015 Apr; 41(8):734-46. PMID: 25728587.
View in:
PubMed
Bouguen G, Sninsky C, Tang KL, Colombel JF, D'Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C,
Sandborn W
. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015 Mar; 21(3):606-14. PMID: 25581826.
View in:
PubMed
Lichtenstein GR, Hanauer SB,
Sandborn W
. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. PMID: 26491415; PMCID: PMC4609145.
View in:
PubMed
,
PubMed Central
Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT,
Sandborn W
, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 05; 519(7541):57-62. PMID: 25731159; PMCID: PMC4447318.
View in:
PubMed
,
PubMed Central
Bryant RV,
Sandborn W
, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis. 2015 Apr; 9(4):356-66. PMID: 25687206.
View in:
PubMed
Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C,
Sandborn W
, Murray JA, Harismendy O, Chang JT. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. PMID: 25667416; PMCID: PMC4355235.
View in:
PubMed
,
PubMed Central
Boland BS, Boyle DL,
Sandborn W
, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. PMID: 25545378; PMCID: PMC4404151.
View in:
PubMed
,
PubMed Central
Sandborn W
, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015 Apr; 148(4):740-750.e2. PMID: 25644096.
View in:
PubMed
Lopez A, Ford AC, Colombel JF, Reinisch W,
Sandborn W
, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015 May; 47(5):356-64. PMID: 25661014.
View in:
PubMed
Sandborn W
, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar; 41(5):409-18. PMID: 25588902.
View in:
PubMed
Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S,
Sandborn W
, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. PMID: 25222660.
View in:
PubMed
Sandborn W
. Tailoring treatment to the individual patient: drug monitoring. Dig Dis. 2014; 32 Suppl 1:88-91. PMID: 25531358.
View in:
PubMed
Akobeng AA,
Sandborn W
, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Inflamm Bowel Dis. 2014 Nov; 20(11):2132-41. PMID: 25299543.
View in:
PubMed
Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC,
Sandborn W
, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. PMID: 25192499.
View in:
PubMed
Mojtahed A, Khanna R,
Sandborn W
, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014 Nov; 20(11):2092-103. PMID: 25137418.
View in:
PubMed
Mosli MH, Feagan BG, Zou G,
Sandborn W
, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG. Reproducibility of histological assessments of disease activity in UC. Gut. 2015 Nov; 64(11):1765-73. PMID: 25360036.
View in:
PubMed
Khanna R, Zou G, D'Haens G, Feagan BG,
Sandborn W
, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther. 2015 Jan; 41(1):77-86. PMID: 25348809.
View in:
PubMed
Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A,
Sandborn W
, Vermeire S, Feagan BG. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. PMID: 25336114; PMCID: PMC4602247.
View in:
PubMed
,
PubMed Central
D'Haens G,
Sandborn W
, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG. A phase II study of laquinimod in Crohn's disease. Gut. 2015 Aug; 64(8):1227-35. PMID: 25281416; PMCID: PMC4515993.
View in:
PubMed
,
PubMed Central
Khanna R, Bouguen G, Feagan BG, D'Haens G,
Sandborn W
, Dubcenco E, Baker KA, Levesque BG. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014 Oct; 20(10):1850-61. PMID: 25029615.
View in:
PubMed
Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C,
Sandborn W
, Colombel JF, Cosnes J. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015 Jan; 148(1):52-63.e3. PMID: 25241327.
View in:
PubMed
Reinisch W, Colombel JF,
Sandborn W
, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):539-547.e2. PMID: 25245629.
View in:
PubMed
Pola S, Santillan C, Levesque BG, Feagan BG,
Sandborn W
. An overview of magnetic resonance enterography for Crohn's disease. Dig Dis Sci. 2014 Sep; 59(9):2040-9. PMID: 24659238.
View in:
PubMed
Adedokun OJ,
Sandborn W
, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014 Dec; 147(6):1296-1307.e5. PMID: 25173754.
View in:
PubMed
Colombel JF,
Sandborn W
, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov; 109(11):1771-80. PMID: 25155227; PMCID: PMC4223868.
View in:
PubMed
,
PubMed Central
Sandborn W
, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct; 40(8):903-16. PMID: 25146586.
View in:
PubMed
Levesque BG,
Sandborn W
, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015 Jan; 148(1):37-51.e1. PMID: 25127678.
View in:
PubMed
Yadav S, Dave M, Edakkanambeth Varayil J, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sweetser SR, Melton LJ,
Sandborn W
, Loftus EV. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):731-8.e1-6; quiz e41. PMID: 25130936; PMCID: PMC4326614.
View in:
PubMed
,
PubMed Central
Samaan MA, Mosli MH,
Sandborn W
, Feagan BG, D'Haens GR, Dubcenco E, Baker KA, Levesque BG. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014 Aug; 20(8):1465-71. PMID: 24831558.
View in:
PubMed
Khanna R, Levesque BG,
Sandborn W
, Feagan BG. Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Aug; 10(8):478-489. PMID: 28845139.
View in:
PubMed
Sandborn W
. Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014 Sep; 147(3):702-5. PMID: 25046160.
View in:
PubMed
Wolf D, D'Haens G,
Sandborn W
, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):486-97. PMID: 25041859.
View in:
PubMed
Boland BS, Boyle DL,
Sandborn W
, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Chang JT. Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep; 40(5):477-85. PMID: 25041724; PMCID: PMC4143528.
View in:
PubMed
,
PubMed Central
Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P,
Sandborn W
, Sands BE. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. PMID: 24989100.
View in:
PubMed
Dulai PS, Siegel CA, Colombel JF,
Sandborn W
, Peyrin-Biroulet L. Systematic review: Monotherapy with antitumour necrosis factor a agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec; 63(12):1843-53. PMID: 24970900.
View in:
PubMed
Boland BS,
Sandborn W
, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):603-17. PMID: 25110261; PMCID: PMC4129380.
View in:
PubMed
,
PubMed Central
Vande Casteele N,
Sandborn W
. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. PMID: 24951843.
View in:
PubMed
Chang JT,
Sandborn W
, Ernst PB. Studies in human intestinal tissues: is it time to reemphasize research in human immunology? Gastroenterology. 2014 Jul; 147(1):26-30. PMID: 24877864.
View in:
PubMed
Sands BE, Feagan BG, Rutgeerts P, Colombel JF,
Sandborn W
, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. PMID: 24859203.
View in:
PubMed
Mosli MH,
Sandborn W
, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014 Jul; 109(7):994-1004. PMID: 24842338.
View in:
PubMed
Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I,
Sandborn W
, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26; 384(9940):309-18. PMID: 24814090.
View in:
PubMed
Sandborn W
, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35. PMID: 24713173.
View in:
PubMed
Levesque BG, Greenberg GR, Zou G,
Sandborn W
, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1126-35. PMID: 24689499.
View in:
PubMed
Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R,
Sandborn W
, Levesque BG. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. PMID: 24595615.
View in:
PubMed
Mosli MH, Feagan BG,
Sandborn W
, D'haens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014 Mar; 20(3):564-75. PMID: 24412993.
View in:
PubMed
Pola S, Boland BS, Lin GY, Kuo A,
Sandborn W
. Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease. Dig Dis Sci. 2014 Jul; 59(7):1642-4. PMID: 24535249.
View in:
PubMed
Williet N,
Sandborn W
, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1246-56.e6. PMID: 24534550.
View in:
PubMed
Bouguen G, Levesque BG, Pola S, Evans E,
Sandborn W
. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014 Feb; 20(2):231-9. PMID: 24351660.
View in:
PubMed
Egan LJ,
Sandborn W
. Taking a closer look at IBD. Gut. 2014 Feb; 63(2):e1. PMID: 24381262.
View in:
PubMed
Sandborn W
, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1485-93.e2. PMID: 24480677.
View in:
PubMed
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A,
Sandborn W
. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23. PMID: 24394749.
View in:
PubMed
Osterman MT,
Sandborn W
, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014 Apr; 146(4):941-9. PMID: 24361468.
View in:
PubMed
Patel NS, Pola S, Muralimohan R, Zou GY, Santillan C, Patel D, Levesque BG,
Sandborn W
. Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease. Dig Dis Sci. 2014 Apr; 59(4):838-49. PMID: 24323180.
View in:
PubMed
Khanna R, Levesque BG,
Sandborn W
. IBD: Measuring what counts--endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol. 2014 Jan; 11(1):9-10. PMID: 24296581.
View in:
PubMed
Bouguen G, Levesque BG, Pola S, Evans E,
Sandborn W
. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Jun; 12(6):978-85. PMID: 24246770.
View in:
PubMed
Colombel JF,
Sandborn W
, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):423-31.e1. PMID: 24184736.
View in:
PubMed
Bouguen G, Evans E,
Sandborn W
. Azathioprine-induced neuro-psychiatric disorders. J Crohns Colitis. 2014 Feb; 8(2):180. PMID: 24103346.
View in:
PubMed
Feagan BG,
Sandborn W
, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):110-118.e3. PMID: 24067881.
View in:
PubMed
Panaccione R, Colombel JF,
Sandborn W
, D'Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov; 38(10):1236-47. PMID: 24134498; PMCID: PMC4670480.
View in:
PubMed
,
PubMed Central
Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB,
Sandborn W
. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. PMID: 24036054.
View in:
PubMed
Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ,
Sandborn W
. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014 Jan; 63(1):88-95. PMID: 23974954.
View in:
PubMed
Rogler G,
Sandborn W
. Is there still a role for thiopurines in Crohn's disease? Gastroenterology. 2013 Oct; 145(4):714-6. PMID: 23973853.
View in:
PubMed
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF,
Sandborn W
, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. PMID: 23964932.
View in:
PubMed
Sandborn W
, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. PMID: 23964933.
View in:
PubMed
Ferrante M, Colombel JF,
Sandborn W
, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5. PMID: 23954314.
View in:
PubMed
Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, Tremaine WJ,
Sandborn W
, Loftus EV. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013 Aug; 19(9):1858-66. PMID: 23660997; PMCID: PMC4526131.
View in:
PubMed
,
PubMed Central
Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY,
Sandborn W
. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. PMID: 23891974.
View in:
PubMed
Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD,
Sandborn W
, Feagan BG. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Sep; 38(5):447-59. PMID: 23848220.
View in:
PubMed
Colombel JF, Rutgeerts PJ,
Sandborn W
, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):414-22.e5. PMID: 23856361.
View in:
PubMed
Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L,
Sandborn W
. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis. 2013 Jul; 19(8):1645-53. PMID: 23598817.
View in:
PubMed
Reinisch W,
Sandborn W
, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul; 19(8):1700-9. PMID: 23665965.
View in:
PubMed
Sandborn W
, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):96-109.e1. PMID: 23770005.
View in:
PubMed
Sandborn W
, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. PMID: 23730956.
View in:
PubMed
Sandborn W
, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):85-95; quiz e14-5. PMID: 23735746.
View in:
PubMed
Afif W,
Sandborn W
, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun; 19(7):1384-9. PMID: 23535248.
View in:
PubMed
Pola S, Fahmy M, Evans E, Tipps A,
Sandborn W
. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013 May; 108(5):857-8. PMID: 23644970.
View in:
PubMed
Rieder F, Zimmermann EM, Remzi FH,
Sandborn W
. Crohn's disease complicated by strictures: a systematic review. Gut. 2013 Jul; 62(7):1072-84. PMID: 23626373; PMCID: PMC4884453.
View in:
PubMed
,
PubMed Central
Herfarth HH, Katz JA, Hanauer SB,
Sandborn W
, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. PMID: 23511031; PMCID: PMC4596532.
View in:
PubMed
,
PubMed Central
Sinakos E, Samuel S, Enders F, Loftus EV,
Sandborn W
, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr; 19(5):1004-9. PMID: 23502353.
View in:
PubMed
Feagan BG,
Sandborn W
, D'Haens G, Pola S, McDonald JW, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):149-157.e2. PMID: 23528626.
View in:
PubMed
Sandborn W
, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis. 2013 Dec; 7(12):958-67. PMID: 23517933.
View in:
PubMed
Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Löwenberg M, Jairath V, Travis SP,
Sandborn W
, Feagan BG, D'Haens GR. Biosimilars in IBD: hope or expectation? Gut. 2013 Jun; 62(6):803-7. PMID: 23503043.
View in:
PubMed
Sandborn W
, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin. 2013 May; 29(5):483-93. PMID: 23438483.
View in:
PubMed
Mayer L,
Sandborn W
, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar; 63(3):442-50. PMID: 23461895; PMCID: PMC3933070.
View in:
PubMed
,
PubMed Central
Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J,
Sandborn W
, Loftus EV, Kappelman MD, Lewis JD, Parkos CA, Sartor RB. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):677-82. PMID: 23448796; PMCID: PMC3740342.
View in:
PubMed
,
PubMed Central
Abboud R, Pardi DS, Tremaine WJ, Kammer PP,
Sandborn W
, Loftus EV. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis. 2013 Mar; 19(3):550-3. PMID: 23380937.
View in:
PubMed
Fahmy M, Shabaik A,
Sandborn W
. Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):E57-8. PMID: 22552963.
View in:
PubMed
Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M,
Sandborn W
. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar; 63(3):433-41. PMID: 23436336; PMCID: PMC3933176.
View in:
PubMed
,
PubMed Central
Sandborn W
, Travis S, Ballard D. Reply: budesonide. Gastroenterology. 2013 Mar; 144(3):e23-4. PMID: 23357061.
View in:
PubMed
Velayos FS, Kahn JG,
Sandborn W
, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun; 11(6):654-66. PMID: 23357488.
View in:
PubMed
Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM,
Sandborn W
, Loftus EV, Wolff BG, Smyrk TC, Itzkowitz SH, Rubin DT, Zou H, Mahoney DW, Ahlquist DA. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54. PMID: 23347191; PMCID: PMC3869396.
View in:
PubMed
,
PubMed Central
Relling MV, Gardner EE,
Sandborn W
, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013 Apr; 93(4):324-5. PMID: 23422873; PMCID: PMC3604643.
View in:
PubMed
,
PubMed Central
Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S,
Sandborn W
. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012 Dec; 107(12):1770-6. PMID: 23211844.
View in:
PubMed
Sandborn W
, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan; 37(2):204-13. PMID: 23173821.
View in:
PubMed
Lichtenstein GR, Hanauer SB,
Sandborn W
. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. PMID: 24847181; PMCID: PMC4027896.
View in:
PubMed
,
PubMed Central
Sandborn W
, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. PMID: 23075178.
View in:
PubMed
Levesque BG,
Sandborn W
. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet. 2012 Dec 01; 380(9857):1887-8. PMID: 23063315.
View in:
PubMed
Sandborn W
, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013 Jan; 108(1):90-8. PMID: 23044768; PMCID: PMC3538174.
View in:
PubMed
,
PubMed Central
Seminerio JL, Loftus EV, Colombel JF, Thapa P,
Sandborn W
. Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013 Mar; 58(3):797-806. PMID: 23053885.
View in:
PubMed
D'Haens G, Feagan B, Colombel JF,
Sandborn W
, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012 Dec; 143(6):1461-9. PMID: 23000597.
View in:
PubMed
Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR,
Sandborn W
, Loftus EV. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012 Nov; 107(11):1693-701. PMID: 22945286; PMCID: PMC3572861.
View in:
PubMed
,
PubMed Central
Baumgart DC,
Sandborn W
. Crohn's disease. Lancet. 2012 Nov 03; 380(9853):1590-605. PMID: 22914295.
View in:
PubMed
Ordás I, Eckmann L, Talamini M, Baumgart DC,
Sandborn W
. Ulcerative colitis. Lancet. 2012 Nov 03; 380(9853):1606-19. PMID: 22914296.
View in:
PubMed
Sandborn W
, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16; 367(7):616-24. PMID: 22894574.
View in:
PubMed
Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR,
Sandborn W
. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):49-54.e1. PMID: 22902762.
View in:
PubMed
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A,
Sandborn W
. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22. PMID: 22890223; PMCID: PMC3438468.
View in:
PubMed
,
PubMed Central
Sandborn W
, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov; 143(5):1218-26.e1-2. PMID: 22892337.
View in:
PubMed
Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera-Nieves J, Chang JT, Evans E, Docherty M, Talamini M,
Sandborn W
. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1315-1325.e4. PMID: 22835577; PMCID: PMC4226798.
View in:
PubMed
,
PubMed Central
Ordás I, Feagan BG,
Sandborn W
. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Oct; 10(10):1079-87; quiz e85-6. PMID: 22813440.
View in:
PubMed
Mohabbat AB,
Sandborn W
, Loftus EV, Wiesner RH, Bruining DH. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012 Sep; 36(6):569-74. PMID: 22779779.
View in:
PubMed
Schreiber S, Reinisch W, Colombel JF,
Sandborn W
, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013 Apr; 7(3):213-21. PMID: 22704916.
View in:
PubMed
Lichtenstein GR, Rutgeerts P,
Sandborn W
, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Jul; 107(7):1051-63. PMID: 22613901; PMCID: PMC3390465.
View in:
PubMed
,
PubMed Central
D'Haens G,
Sandborn W
, Barrett K, Hodgson I, Streck P. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012 Jul; 107(7):1064-77. PMID: 22565161.
View in:
PubMed
Fahmy M, Ramamoorthy S, Hata T,
Sandborn W
. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012 May; 107(5):794-5. PMID: 22552250.
View in:
PubMed
Sands BE,
Sandborn W
, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012 Aug; 143(2):356-64.e1. PMID: 22549092.
View in:
PubMed
Sandborn W
, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. PMID: 22504093.
View in:
PubMed
Samuel S, Bruining DH, Loftus EV, Becker B, Fletcher JG, Mandrekar JN, Zinsmeister AR,
Sandborn W
. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1253-9. PMID: 22503995.
View in:
PubMed
Kane SV, Horst S,
Sandborn W
, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012 Dec; 18(12):2203-8. PMID: 22419661.
View in:
PubMed
Ordás I, Mould DR, Feagan BG,
Sandborn W
. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr; 91(4):635-46. PMID: 22357456.
View in:
PubMed
Rutgeerts P, Van Assche G,
Sandborn W
, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May; 142(5):1102-1111.e2. PMID: 22326435.
View in:
PubMed
Hommes D, Colombel JF, Emery P, Greco M,
Sandborn W
. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012 Feb; 6 Suppl 2:S224-34. PMID: 22463929.
View in:
PubMed
Sandborn W
. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):117-9. PMID: 22485079; PMCID: PMC3317509.
View in:
PubMed
,
PubMed Central
Pineton de Chambrun GP,
Sandborn W
. IBD in 2011: Advances in IBD management--towards a tailored approach. Nat Rev Gastroenterol Hepatol. 2012 Jan 10; 9(2):70-2. PMID: 22230905.
View in:
PubMed
Nguyen DL,
Sandborn W
, Loftus EV, Larson DW, Fletcher JG, Becker B, Mandrekar J, Harmsen WS, Bruining DH. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):400-4. PMID: 22155562.
View in:
PubMed
Ford AC, Khan KJ,
Sandborn W
, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. PMID: 22083024.
View in:
PubMed
Sandborn W
, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb; 142(2):257-65.e1-3. PMID: 22062358.
View in:
PubMed
Colombel JF, Feagan BG,
Sandborn W
, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012 Feb; 18(2):349-58. PMID: 22021134.
View in:
PubMed
Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY,
Sandborn W
. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. PMID: 21997563; PMCID: PMC3292713.
View in:
PubMed
,
PubMed Central
Ordás I, Feagan BG,
Sandborn W
. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011 Dec; 60(12):1754-63. PMID: 21997558.
View in:
PubMed
Cipriano LE, Levesque BG, Zaric GS, Loftus EV,
Sandborn W
. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2012 Jul; 18(7):1240-8. PMID: 21928375.
View in:
PubMed
Ford AC, Khan KJ,
Sandborn W
, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. PMID: 21894226.
View in:
PubMed
Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA,
Sandborn W
, Travis SP, Colombel JF. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PMID: 21844919.
View in:
PubMed
Sandborn W
, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56. PMID: 21848857.
View in:
PubMed
Levesque BG,
Sandborn W
. Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. Inflamm Bowel Dis. 2012 Apr; 18(4):795-6. PMID: 21739537.
View in:
PubMed
Samuel S, Loftus EV,
Sandborn W
. Henoch-schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum. Dig Dis Sci. 2011 Jul; 56(7):2205-6. PMID: 21249449.
View in:
PubMed
Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE,
Sandborn W
. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. PMID: 21723220.
View in:
PubMed
Peyrin-Biroulet L, Cieza A,
Sandborn W
, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012 Feb; 61(2):241-7. PMID: 21646246; PMCID: PMC3245899.
View in:
PubMed
,
PubMed Central
Kamm MA, Hanauer SB, Panaccione R, Colombel JF,
Sandborn W
, Pollack PF, Zhou Q, Robinson AM. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17. PMID: 21645018.
View in:
PubMed
Sandborn W
, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):670-678.e3. PMID: 21642014.
View in:
PubMed
Bruining DH, Loftus EV, Ehman EC, Siddiki HA, Nguyen DL, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS,
Sandborn W
, Fletcher JG. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):679-683.e1. PMID: 21621641.
View in:
PubMed
Reinisch W,
Sandborn W
, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. PMID: 21484965.
View in:
PubMed
Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV,
Sandborn W
, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. PMID: 21472012.
View in:
PubMed
Garrity-Park M, Loftus EV,
Sandborn W
, Smyrk TC. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012 Feb; 18(2):275-83. PMID: 21425209.
View in:
PubMed
Kisiel JB, Loftus EV, Harmsen WS, Zinsmeister AR,
Sandborn W
. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012 Feb; 18(2):226-35. PMID: 21416564.
View in:
PubMed
Billioud V,
Sandborn W
, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011 Apr; 106(4):674-84. PMID: 21407178.
View in:
PubMed
Ford AC,
Sandborn W
, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. PMID: 21407183.
View in:
PubMed
Sandborn W
. Why innovation in inflammatory bowel disease drug development will impact your practice. Clin Gastroenterol Hepatol. 2011 Mar; 9(3):211-3. PMID: 21338946.
View in:
PubMed
Siddiki H, Fletcher JG, Hara AK, Kofler JM, McCollough CH, Fidler JL, Guimaraes L, Huprich JE,
Sandborn W
, Loftus EV, Mandrekar J, Bruining DH. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel. Inflamm Bowel Dis. 2011 Mar; 17(3):778-86. PMID: 20848546.
View in:
PubMed
Peyrin-Biroulet L, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR,
Sandborn W
. Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012 Jan; 18(1):43-8. PMID: 21351216; PMCID: PMC3352677.
View in:
PubMed
,
PubMed Central
Bruining DH, Siddiki HA, Fletcher JG,
Sandborn W
, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Evans PE, Faubion WA, Hanson KA, Ingle SB, Pardi DS, Schroeder KW, Tremaine WJ, Loftus EV. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis. 2012 Feb; 18(2):219-25. PMID: 21337477.
View in:
PubMed
Bruining DH,
Sandborn W
. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011 May; 9(5):395-9. PMID: 21277392.
View in:
PubMed
Relling MV, Gardner EE,
Sandborn W
, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar; 89(3):387-91. PMID: 21270794; PMCID: PMC3098761.
View in:
PubMed
,
PubMed Central
Levesque BG, Hanson KA,
Sandborn W
. Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch. Gastroenterology. 2011 Mar; 140(3):1107-8; author reply 1108-9. PMID: 21272556.
View in:
PubMed
Feagan BG,
Sandborn W
, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar; 33(5):541-50. PMID: 21223344.
View in:
PubMed
Reinisch W,
Sandborn W
, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. PMID: 21209123.
View in:
PubMed
Sandborn W
, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011 Jan; 17(1):141-51. PMID: 20848500.
View in:
PubMed
Thia K, Faubion WA, Loftus EV, Persson T, Persson A,
Sandborn W
. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis. 2011 Jan; 17(1):105-11. PMID: 20629100.
View in:
PubMed
Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP,
Sandborn W
, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224. PMID: 21157441.
View in:
PubMed
Hanauer SB, Kornbluth AA, Messick J, Rubin DT,
Sandborn W
, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. PMID: 21104734.
View in:
PubMed
Tang T, Targan SR, Li ZS, Xu C, Byers VS,
Sandborn W
. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011 Jan; 33(2):194-202. PMID: 21114791.
View in:
PubMed
Pariente B, Cosnes J, Danese S,
Sandborn W
, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011 Jun; 17(6):1415-22. PMID: 21560202; PMCID: PMC3116198.
View in:
PubMed
,
PubMed Central
Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R,
Sandborn W
. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93. PMID: 21083671.
View in:
PubMed
D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B,
Sandborn W
, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. PMID: 21045814.
View in:
PubMed
Samuel S, Loftus EV,
Sandborn W
. The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis. Aliment Pharmacol Ther. 2010 Nov; 32(9):1207-9. PMID: 21039684.
View in:
PubMed
Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR,
Sandborn W
. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16(11):1912-21. PMID: 20848486.
View in:
PubMed
Sandborn W
, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010 Nov; 59(11):1485-92. PMID: 20947884.
View in:
PubMed
Levesque BG,
Sandborn W
. Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2011 Jun; 17(6):1443-4. PMID: 21560204.
View in:
PubMed
Sandborn W
. State-of-the-art: Immunosuppression and biologic therapy. Dig Dis. 2010; 28(3):536-42. PMID: 20926883.
View in:
PubMed
Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR,
Sandborn W
. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17(6):1257-64. PMID: 20878712.
View in:
PubMed
Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG,
Sandborn W
, Loftus EV, Larson DW. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg. 2010 Dec; 14(12):1859-65; discussion 1865-6. PMID: 20872084.
View in:
PubMed
Peyrin-Biroulet L, Loftus EV, Colombel JF,
Sandborn W
. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan; 17(1):471-8. PMID: 20725943.
View in:
PubMed
Thia KT,
Sandborn W
, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010 Oct; 139(4):1147-55. PMID: 20637205; PMCID: PMC2950117.
View in:
PubMed
,
PubMed Central
Holubar SD, Cima RR,
Sandborn W
, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010 Jun 16; (6):CD001176. PMID: 20556748.
View in:
PubMed
Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S,
Sandborn W
. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93. PMID: 20491747.
View in:
PubMed
Sandborn W
, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):688-695.e2. PMID: 20451663.
View in:
PubMed
Colombel JF,
Sandborn W
, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15; 362(15):1383-95. PMID: 20393175.
View in:
PubMed
Oussalah A, Chevaux JB, Fay R,
Sandborn W
, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010 May; 105(5):1142-9. PMID: 20389296.
View in:
PubMed
Sandborn W
, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. PMID: 20363366.
View in:
PubMed
Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB,
Sandborn W
. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. PMID: 19714757.
View in:
PubMed
Panaccione R, Colombel JF,
Sandborn W
, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Jun; 31(12):1296-309. PMID: 20298496.
View in:
PubMed
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J,
Sandborn W
. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul; 105(7):1574-82. PMID: 20234346.
View in:
PubMed
Sandborn W
. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis. 2009; 27 Suppl 1:80-4. PMID: 20203501.
View in:
PubMed
Garrity-Park MM, Loftus EV,
Sandborn W
, Bryant SC, Smyrk TC. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010 Jul; 105(7):1610-9. PMID: 20160714.
View in:
PubMed
Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA,
Sandborn W
. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. PMID: 20145610.
View in:
PubMed
Peyrin-Biroulet L, Loftus EV, Colombel JF,
Sandborn W
. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010 Feb; 59(2):141-7. PMID: 20176633.
View in:
PubMed
Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R,
Sandborn W
. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. PMID: 20117244.
View in:
PubMed
Guimarães LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H,
Sandborn W
, Loftus EV, Pardi DS, McCollough CH. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010 Feb; 16(2):226-32. PMID: 19637359.
View in:
PubMed
Vermeire S, Schreiber S,
Sandborn W
, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010 Apr; 8(4):357-63. PMID: 20096379.
View in:
PubMed
Sandborn W
, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. PMID: 20064514.
View in:
PubMed
Malireddy K, Larson DW,
Sandborn W
, Loftus EV, Faubion WA, Pardi DS, Qin R, Gullerud RE, Cima RR, Wolff B, Dozois EJ. Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg. 2010 Jan; 145(1):42-7. PMID: 20083753.
View in:
PubMed
Peyrin-Biroulet L, Cieza A,
Sandborn W
, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010 Jan; 16(1):15-22. PMID: 19610077.
View in:
PubMed
Peyrin-Biroulet L, Loftus EV, Colombel JF,
Sandborn W
. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb; 105(2):289-97. PMID: 19861953.
View in:
PubMed
D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S,
Sandborn W
. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1599-604. PMID: 19653291.
View in:
PubMed
Sandborn W
, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. PMID: 19766640.
View in:
PubMed
Colombel JF,
Sandborn W
, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1308-19. PMID: 19434735.
View in:
PubMed
Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA,
Sandborn W
. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. PMID: 19408340.
View in:
PubMed
Ravi K, Chari ST, Vege SS,
Sandborn W
, Smyrk TC, Loftus EV. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009 Sep; 15(9):1326-30. PMID: 19235915.
View in:
PubMed
Manabe N, Cremonini F, Camilleri M,
Sandborn W
, Burton DD. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther. 2009 Nov 01; 30(9):930-6. PMID: 19678812; PMCID: PMC2862903.
View in:
PubMed
,
PubMed Central
Toedter GP, Blank M, Lang Y, Chen D,
Sandborn W
, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2768-73. PMID: 19672253.
View in:
PubMed
Velayos FS,
Sandborn W
. Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol. 2009 Aug; 104(8):2097-9. PMID: 19661939.
View in:
PubMed
Sandborn W
, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. PMID: 19596014.
View in:
PubMed
Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV,
Sandborn W
, Pardi DS, Mandrekar JN. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol. 2009 Jul; 193(1):113-21. PMID: 19542402.
View in:
PubMed
Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA,
Sandborn W
, Loftus EV. CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom Imaging. 2009 Jul; 34(4):467-75. PMID: 18551336.
View in:
PubMed
Marehbian J, Arrighi HM, Hass S, Tian H,
Sandborn W
. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009 Oct; 104(10):2524-33. PMID: 19532125.
View in:
PubMed
Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T,
Sandborn W
, Parenti D, Lee K, Reinisch W. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. PMID: 19130617.
View in:
PubMed
Peyrin-Biroulet L, Colombel JF,
Sandborn W
. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol. 2009 Oct; 7(10):1139. PMID: 19465159.
View in:
PubMed
Hanson KA, Loftus EV, Harmsen WS, Diehl NN, Zinsmeister AR,
Sandborn W
. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis. 2009 May; 15(5):772-7. PMID: 19107782.
View in:
PubMed
Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y,
Sandborn W
. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009 Aug; 30(3):210-26. PMID: 19392858.
View in:
PubMed
Colombel JF,
Sandborn W
, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. PMID: 19352339.
View in:
PubMed
Loftus EV, Friedman HS, Delgado DJ,
Sandborn W
. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis. 2009 Apr; 15(4):566-75. PMID: 19143006.
View in:
PubMed
Garrity-Park MM, Loftus EV,
Sandborn W
, Bryant SC, Smyrk TC. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut. 2009 Sep; 58(9):1226-33. PMID: 19251712.
View in:
PubMed
Baumgart DC, Lowder JN, Targan SR,
Sandborn W
, Frankel MB. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol. 2009 Apr; 104(4):868-76. PMID: 19240707.
View in:
PubMed
Colombel JF, Schwartz DA,
Sandborn W
, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul; 58(7):940-8. PMID: 19201775; PMCID: PMC2689393.
View in:
PubMed
,
PubMed Central
Lichtenstein GR, Hanauer SB,
Sandborn W
. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. PMID: 19174807.
View in:
PubMed
Kamm MA, Lichtenstein GR,
Sandborn W
, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8. PMID: 18671232.
View in:
PubMed
Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN,
Sandborn W
. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009 Jan; 15(1):17-24. PMID: 18668682.
View in:
PubMed
Sandborn W
. The future of inflammatory bowel disease care. Rev Gastroenterol Disord. 2009; 9(3):E69-77. PMID: 19898267.
View in:
PubMed
Jones J, Chen LS, Baudhuin L, Peterson S, Harmsen WS, Zinsmeister AR, McConnell J,
Sandborn W
. Relationships between C-reactive protein concentration and genotype in healthy volunteers. Clin Chem Lab Med. 2009; 47(1):20-5. PMID: 19072030.
View in:
PubMed
Thia KT, Loftus EV,
Sandborn W
, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008 Dec; 103(12):3167-82. PMID: 19086963.
View in:
PubMed
Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ,
Sandborn W
, Loftus EV. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis. 2008 Dec; 14(12):1701-6. PMID: 18623171.
View in:
PubMed
Thia KT,
Sandborn W
, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. PMID: 18786111.
View in:
PubMed
Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, McQuaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA,
Sandborn W
, Todisco A. AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States. Gastroenterology. 2008 Nov; 135(5):1764-89.e2. PMID: 19009690.
View in:
PubMed
Sandborn W
. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008 Nov; 135(5):1442-7. PMID: 18848556.
View in:
PubMed
Sandborn W
. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S232-3. PMID: 18816658.
View in:
PubMed
Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E,
Sandborn W
. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008 Nov; 6(11):1218-24. PMID: 18799360.
View in:
PubMed
Panaccione R, Rutgeerts P,
Sandborn W
, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Sep 15; 28(6):674-88. PMID: 18532990.
View in:
PubMed
Feagan BG, Panaccione R,
Sandborn W
, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. PMID: 18848553.
View in:
PubMed
Sandborn W
, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008 Oct; 135(4):1130-41. PMID: 18706417.
View in:
PubMed
Peyrin-Biroulet L, Desreumaux P,
Sandborn W
, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008 Jul 05; 372(9632):67-81. PMID: 18603161.
View in:
PubMed
Sandborn W
. Certolizumab Pegol for Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2008 Jul; 4(7):467-8. PMID: 21960919; PMCID: PMC3096126.
View in:
PubMed
,
PubMed Central
Loftus EV, Delgado DJ, Friedman HS,
Sandborn W
. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008 Jul; 103(7):1737-45. PMID: 18564126.
View in:
PubMed
Peloquin JM, Pardi DS,
Sandborn W
, Fletcher JG, McCollough CH, Schueler BA, Kofler JA, Enders FT, Achenbach SJ, Loftus EV. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008 Aug; 103(8):2015-22. PMID: 18564113; PMCID: PMC2831296.
View in:
PubMed
,
PubMed Central
Solem CA, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR,
Sandborn W
. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug; 68(2):255-66. PMID: 18513722.
View in:
PubMed
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J,
Sandborn W
, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun; 6(6):644-53. PMID: 18550004.
View in:
PubMed
Geboes K, Colombel JF, Greenstein A, Jewell DP,
Sandborn W
, Vatn MH, Warren B, Riddell RH. Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis. 2008 Jun; 14(6):850-7. PMID: 18213696.
View in:
PubMed
Sands BE,
Sandborn W
, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. PMID: 18602921.
View in:
PubMed
Feagan BG,
Sandborn W
, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008 Apr 09; 299(14):1690-7. PMID: 18398081.
View in:
PubMed
Sandborn W
. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008 Apr; 42(4):338-44. PMID: 18277908.
View in:
PubMed
Lichtenstein GR, Kamm MA,
Sandborn W
, Lyne A, Joseph RE. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008 Jun 01; 27(11):1094-102. PMID: 18363894.
View in:
PubMed
Sandborn W
. Initial combination therapy in early Crohn's disease. Lancet. 2008 Feb 23; 371(9613):635-636. PMID: 18295013.
View in:
PubMed
Kamm MA, Lichtenstein GR,
Sandborn W
, Schreiber S, Lees K, Barrett K, Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008 Jul; 57(7):893-902. PMID: 18272546; PMCID: PMC2564831.
View in:
PubMed
,
PubMed Central
Garrity-Park MM, Loftus EV, Bryant SC,
Sandborn W
, Smyrk TC. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008 Feb; 103(2):407-15. PMID: 18289203.
View in:
PubMed
Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R,
Sandborn W
, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr; 134(4):929-36. PMID: 18294633.
View in:
PubMed
Sandborn W
. Mucosal healing in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(4):271-2. PMID: 19107101.
View in:
PubMed
Velayos FS,
Sandborn W
. Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2007 Dec; 9(6):521-7. PMID: 18377806.
View in:
PubMed
Hanauer SB,
Sandborn W
, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34. PMID: 18080055; PMCID: PMC2658575.
View in:
PubMed
,
PubMed Central
Feagan BG,
Sandborn W
, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007 Dec; 102(12):2737-46. PMID: 18042106.
View in:
PubMed
Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D,
Sandborn W
. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. PMID: 17567869.
View in:
PubMed
Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I,
Sandborn W
, Loftus EV, Pemberton JH. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis. 2007 Oct; 13(10):1266-70. PMID: 17567877.
View in:
PubMed
Sandborn W
, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007 Oct 01; 26(7):987-1003. PMID: 17877506.
View in:
PubMed
Reinisch W,
Sandborn W
, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Sep; 13(9):1135-40. PMID: 17476675.
View in:
PubMed
Winter TA,
Sandborn W
, de Villiers WJ, Schreiber S. Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol. 2007 Sep; 3(5):683-94. PMID: 20477019.
View in:
PubMed
Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D,
Sandborn W
, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. PMID: 17920064.
View in:
PubMed
Mahadevan U,
Sandborn W
, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. PMID: 17764676.
View in:
PubMed
Sandborn W
, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):228-38. PMID: 17634458.
View in:
PubMed
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R,
Sandborn W
. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. PMID: 17634459.
View in:
PubMed
Sandborn W
, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007 Jul 15; 26(2):205-15. PMID: 17593066.
View in:
PubMed
Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P,
Sandborn W
, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. PMID: 17631151.
View in:
PubMed
Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS,
Sandborn W
, Harmsen WS, Thapa P, Zinsmeister AR. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther. 2007 Jun 15; 25(12):1435-41. PMID: 17539983.
View in:
PubMed
Camilleri M,
Sandborn W
, Kolars JC, Murray JA, Poterucha JJ, Roberts L, Sinicrope FA, Wang KK. A moveable feast. Clin Gastroenterol Hepatol. 2007 Jun; 5(6):646-7. PMID: 17544990.
View in:
PubMed
Baumgart DC,
Sandborn W
. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12; 369(9573):1641-57. PMID: 17499606.
View in:
PubMed
Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV,
Sandborn W
, Wolff BG, Pemberton JH. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007 May; 204(5):956-62; discussion 962-3. PMID: 17481518.
View in:
PubMed
Sandborn W
, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. PMID: 17470824.
View in:
PubMed
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J,
Sandborn W
. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007 May; 132(5):1672-83. PMID: 17484865.
View in:
PubMed
Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ,
Sandborn W
. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007 Mar; 13(3):254-61. PMID: 17206702.
View in:
PubMed
Feagan BG, Reinisch W, Rutgeerts P,
Sandborn W
, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. PMID: 17324131.
View in:
PubMed
Sandborn W
, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9. PMID: 17299059; PMCID: PMC2701613.
View in:
PubMed
,
PubMed Central
Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ,
Sandborn W
. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):175-81. PMID: 17206699.
View in:
PubMed
Hanauer SB,
Sandborn W
. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3. PMID: 17303600; PMCID: PMC1856750.
View in:
PubMed
,
PubMed Central
Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P,
Sandborn W
. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007 Apr; 102(4):829-36. PMID: 17222314.
View in:
PubMed
Desai D, Faubion WA,
Sandborn W
. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007 Feb 01; 25(3):247-55. PMID: 17217454.
View in:
PubMed
Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE,
Sandborn W
. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102. PMID: 17234558.
View in:
PubMed
Hanauer SB,
Sandborn W
. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. PMID: 17392632.
View in:
PubMed
Sandborn W
. Clinical perspectives in Crohn's disease: now and in the future. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S1-2. PMID: 17392634.
View in:
PubMed
Sandborn W
. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S23-35. PMID: 17392636.
View in:
PubMed
Sandborn W
. A new treatment option for ulcerative colitis. Rev Gastroenterol Disord. 2007; 7(2):106-7. PMID: 17597673.
View in:
PubMed
Sandborn W
. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):16-7. PMID: 21960772; PMCID: PMC3096114.
View in:
PubMed
,
PubMed Central
D'Haens G,
Sandborn W
, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. PMID: 17258735.
View in:
PubMed
Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS,
Sandborn W
, Faubion WA. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006 Dec; 12(12):1093-100. PMID: 17119382.
View in:
PubMed
Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ,
Sandborn W
. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007 Apr; 56(4):504-8. PMID: 17135309; PMCID: PMC1856874.
View in:
PubMed
,
PubMed Central
Colombel JF,
Sandborn W
, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. PMID: 17241859.
View in:
PubMed
Kamm MA,
Sandborn W
, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3. PMID: 17241860.
View in:
PubMed
Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA,
Sandborn W
, Loftus EV, Harmsen WS. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006 Dec; 241(3):787-95. PMID: 17032911.
View in:
PubMed
Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ, Munkholm P,
Sandborn W
. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006 Aug; 12(8):669-76. PMID: 16917220.
View in:
PubMed
Sands BE, Kilgore KM, Bloomfeld RS,
Sandborn W
. Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. J Clin Gastroenterol. 2006 Aug; 40(7):587-91. PMID: 16917398.
View in:
PubMed
Laing AW, Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ,
Sandborn W
. Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bowel Dis. 2006 Aug; 12(8):708-11. PMID: 16917225.
View in:
PubMed
Sands BE,
Sandborn W
, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. PMID: 16825929.
View in:
PubMed
Rutgeerts P,
Sandborn W
, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):888-93. PMID: 16797249.
View in:
PubMed
Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ,
Sandborn W
. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006 Jun; 130(7):1941-9. PMID: 16762617.
View in:
PubMed
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML,
Sandborn W
. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30. PMID: 16678077.
View in:
PubMed
Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB,
Sandborn W
. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. PMID: 16606351.
View in:
PubMed
Schreiber S,
Sandborn W
. CLASSIC-I study the efficacy of adalimumab. Gastroenterology. 2006 May; 130(6):1929-30. PMID: 16697761.
View in:
PubMed
Sandborn W
. What's new: innovative concepts in inflammatory bowel disease. Colorectal Dis. 2006 May; 8 Suppl 1:3-9. PMID: 16594957.
View in:
PubMed
Colombel JF, Solem CA,
Sandborn W
, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006 Nov; 55(11):1561-7. PMID: 16648154; PMCID: PMC1860143.
View in:
PubMed
,
PubMed Central
Pardi DS,
Sandborn W
. Systematic review: the management of pouchitis. Aliment Pharmacol Ther. 2006 Apr 15; 23(8):1087-96. PMID: 16611268.
View in:
PubMed
Van Assche G,
Sandborn W
, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006 Nov; 55(11):1568-74. PMID: 16603634; PMCID: PMC1860086.
View in:
PubMed
,
PubMed Central
Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P,
Sandborn W
. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006 Apr; 130(4):1039-46. PMID: 16618397.
View in:
PubMed
Feagan BG,
Sandborn W
, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006 Mar 01; 23(5):617-28. PMID: 16480401.
View in:
PubMed
Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH,
Sandborn W
, Loftus EV, Harmsen WS, Crownhart BS. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology. 2006 Feb; 238(2):505-16. PMID: 16436815.
View in:
PubMed
Hanauer SB,
Sandborn W
, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591. PMID: 16472588.
View in:
PubMed
Sandborn W
, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb; 4(2):203-11. PMID: 16469681.
View in:
PubMed
Jess T, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Munkholm P,
Sandborn W
. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006 Sep; 55(9):1248-54. PMID: 16423890; PMCID: PMC1860022.
View in:
PubMed
,
PubMed Central
Hanauer SB,
Sandborn W
, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89. PMID: 16957658.
View in:
PubMed
Sandborn W
. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord. 2006; 6(2):97-105. PMID: 16699478.
View in:
PubMed
Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA,
Sandborn W
. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006 Jan; 12(1):29-32. PMID: 16374255.
View in:
PubMed
Sandborn W
. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S15-21. PMID: 16378006.
View in:
PubMed
Rutgeerts P,
Sandborn W
, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76. PMID: 16339095.
View in:
PubMed
Moolsintong P, Loftus EV, Chari ST, Egan LJ, Tremaine WJ,
Sandborn W
. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005 Dec; 11(12):1080-4. PMID: 16306770.
View in:
PubMed
Egan LJ,
Sandborn W
. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2005 Dec; 7(6):485-91. PMID: 16313879.
View in:
PubMed
Sandborn W
, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25. PMID: 16267322.
View in:
PubMed
Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD,
Sandborn W
, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8. PMID: 16254479.
View in:
PubMed
Isaacs KL, Lewis JD,
Sandborn W
, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S3-12. PMID: 16254481.
View in:
PubMed
Hanauer SB,
Sandborn W
, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85. PMID: 16279903.
View in:
PubMed
Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S,
Sandborn W
. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct; 100(10):2239-47. PMID: 16181376.
View in:
PubMed
Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR,
Sandborn W
. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Aug; 11(8):707-12. PMID: 16043984.
View in:
PubMed
Sandborn W
, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7. PMID: 16086715.
View in:
PubMed
Larson DW, Dozois E,
Sandborn W
, Cima R. Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis. Surg Endosc. 2005 Sep; 19(9):1284-7. PMID: 16132322.
View in:
PubMed
Toruner M, Harewood GC, Loftus EV,
Sandborn W
, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2005 May; 11(5):428-34. PMID: 15867581.
View in:
PubMed
Mahadevan U, Kane S,
Sandborn W
, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8. PMID: 15771759.
View in:
PubMed
Pardi DS,
Sandborn W
. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut. 2005 Mar; 54(3):321-2. PMID: 15710974; PMCID: PMC1774419.
View in:
PubMed
,
PubMed Central
Feagan BG,
Sandborn W
, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84. PMID: 15709987.
View in:
PubMed
Hanauer S,
Sandborn W
, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71. PMID: 15709986.
View in:
PubMed
Sandborn W
. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord. 2005; 5(1):10-8. PMID: 15741928.
View in:
PubMed
Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA,
Sandborn W
. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005 Jan; 54(1):91-6. PMID: 15591511; PMCID: PMC1774346.
View in:
PubMed
,
PubMed Central
Sandborn W
. Inflammatory bowel disease: a new combination therapy for pouchitis. Rev Gastroenterol Disord. 2005; 5(2):110. PMID: 15976743.
View in:
PubMed
Sandborn W
, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004 Dec; 127(6):1809-14. PMID: 15578518.
View in:
PubMed
Mannon PJ, Fuss IJ, Mayer L, Elson CO,
Sandborn W
, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004 Nov 11; 351(20):2069-79. PMID: 15537905.
View in:
PubMed
Sandborn W
, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. PMID: 15447761.
View in:
PubMed
Sandborn W
, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004 Oct; 53(10):1485-93. PMID: 15361500; PMCID: PMC1774244.
View in:
PubMed
,
PubMed Central
Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ,
Sandborn W
, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005 Feb; 312(2):537-45. PMID: 15388785.
View in:
PubMed
Velayos FS,
Sandborn W
. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):657-60. PMID: 15472531.
View in:
PubMed
Sandborn W
, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology. 2004 Sep; 127(3):990-3. PMID: 15362055.
View in:
PubMed
Sandborn W
, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut. 2004 Sep; 53(9):1366-73. PMID: 15306602; PMCID: PMC1774209.
View in:
PubMed
,
PubMed Central
Panaccione R,
Sandborn W
. Medical therapy of Crohn disease. Curr Opin Gastroenterol. 2004 Jul; 20(4):351-9. PMID: 15703664.
View in:
PubMed
Sandborn W
, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004 Jun; 53(6):780-2. PMID: 15138201; PMCID: PMC1774089.
View in:
PubMed
,
PubMed Central
Loftus CG, Egan LJ,
Sandborn W
. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):141-69, vii. PMID: 15177532.
View in:
PubMed
Sandborn W
, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98. PMID: 15142198.
View in:
PubMed
Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD,
Sandborn W
. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004 May; 99(5):878-83. PMID: 15128354.
View in:
PubMed
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR,
Sandborn W
. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004 May; 10(3):207-14. PMID: 15290913.
View in:
PubMed
Egan LJ,
Sandborn W
. Advances in the treatment of Crohn's disease. Gastroenterology. 2004 May; 126(6):1574-81. PMID: 15168368.
View in:
PubMed
Matzke GM, Kang AS, Dozois EJ,
Sandborn W
. Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum. 2004 May; 47(5):782-6. PMID: 15037928.
View in:
PubMed
Sandborn W
. Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis. 2004 Feb; 10 Suppl 1:S35-7. PMID: 15168829.
View in:
PubMed
Colombel JF, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR,
Sandborn W
. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan; 126(1):19-31. PMID: 14699483.
View in:
PubMed
Solem CA, Loftus EV, Tremaine WJ,
Sandborn W
. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004 Jan; 99(1):97-101. PMID: 14687149.
View in:
PubMed
Thomas CW, Weinshenker BG,
Sandborn W
. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Jan; 10(1):28-31. PMID: 15058523.
View in:
PubMed
Sandborn W
. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004; 4(4):167-74. PMID: 15580151.
View in:
PubMed
Sandborn W
. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S25-33. PMID: 15583528.
View in:
PubMed
Sandborn W
. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S1-5. PMID: 14697912.
View in:
PubMed
Sandborn W
. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):501-5. PMID: 14602060.
View in:
PubMed
Sandborn W
, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003 Nov; 98(11):2372-82. PMID: 14638336.
View in:
PubMed
Sandborn W
, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30. PMID: 14598268.
View in:
PubMed
Loftus EV, Achenbach SJ,
Sandborn W
, Tremaine WJ, Oberg AL, Melton LJ. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003 Nov; 1(6):465-73. PMID: 15017646.
View in:
PubMed
Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH,
Sandborn W
. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003 Oct; 98(10):2239-44. PMID: 14572574.
View in:
PubMed
Wold PB, Fletcher JG, Johnson CD,
Sandborn W
. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology. 2003 Oct; 229(1):275-81. PMID: 12944602.
View in:
PubMed
Sandborn W
, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8. PMID: 12891539.
View in:
PubMed
Sandborn W
, Feagan BG. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003 Aug 01; 18(3):263-77. PMID: 12895211.
View in:
PubMed
Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ,
Sandborn W
. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003 Jul; 9(4):237-45. PMID: 12902847.
View in:
PubMed
Sandborn W
, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64. PMID: 12786629.
View in:
PubMed
Kane SV,
Sandborn W
, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. PMID: 12818275.
View in:
PubMed
Mahadevan U,
Sandborn W
. Diagnosis and management of pouchitis. Gastroenterology. 2003 May; 124(6):1636-50. PMID: 12761722.
View in:
PubMed
Elson CO, Sartor RB, Targan SR,
Sandborn W
. Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis. 2003 May; 9(3):137-53. PMID: 12792219.
View in:
PubMed
Sandborn W
. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 2003 Apr; 124(4):1140-5. PMID: 12671907.
View in:
PubMed
Loftus CG, Loftus EV,
Sandborn W
. Cyclosporin for refractory ulcerative colitis. Gut. 2003 Feb; 52(2):172-3. PMID: 12524395; PMCID: PMC1774959.
View in:
PubMed
,
PubMed Central
Sandborn W
. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):105-17. PMID: 12617886.
View in:
PubMed
Sandborn W
, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42. PMID: 12492730.
View in:
PubMed
Sandborn W
. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002 Dec; 97(12):2939-41. PMID: 12492172.
View in:
PubMed
Sandborn W
, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72. PMID: 12492177.
View in:
PubMed
Pardi DS, Ramnath VR, Loftus EV, Tremaine WJ,
Sandborn W
. Lymphocytic colitis: clinical features, treatment, and outcomes. Am J Gastroenterol. 2002 Nov; 97(11):2829-33. PMID: 12425555.
View in:
PubMed
Mahadevan U, Loftus EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR,
Sandborn W
. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002 Sep; 8(5):311-6. PMID: 12479645.
View in:
PubMed
Solem CA, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG,
Sandborn W
. Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol. 2002 Sep; 97(9):2300-5. PMID: 12358248.
View in:
PubMed
Loftus EV, Crowson CS,
Sandborn W
, Tremaine WJ, O'Fallon WM, Melton LJ. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002 Aug; 123(2):468-75. PMID: 12145800.
View in:
PubMed
Kane SV, Schoenfeld P,
Sandborn W
, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002 Aug; 16(8):1509-17. PMID: 12182751.
View in:
PubMed
Ricart E, Taylor WR, Loftus EV, O'Kane D, Weinshilboum RM, Tremaine WJ, Harmsen WS, Zinsmeister AR,
Sandborn W
. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol. 2002 Jul; 97(7):1763-8. PMID: 12135032.
View in:
PubMed
Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD,
Sandborn W
, Loftus EV. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002 May; 8(3):186-91. PMID: 11979139.
View in:
PubMed
Sandborn W
, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002 May; 122(6):1592-608. PMID: 12016425.
View in:
PubMed
Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR,
Sandborn W
. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr; 122(4):875-80. PMID: 11910338.
View in:
PubMed
Pardi DS, Smyrk TC, Tremaine WJ,
Sandborn W
. Microscopic colitis: a review. Am J Gastroenterol. 2002 Apr; 97(4):794-802. PMID: 12003412.
View in:
PubMed
Mahadevan U, Loftus EV, Tremaine WJ,
Sandborn W
. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr; 97(4):910-4. PMID: 12008668.
View in:
PubMed
Ullman TA, Loftus EV, Kakar S, Burgart LJ,
Sandborn W
, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002 Apr; 97(4):922-7. PMID: 12008669.
View in:
PubMed
Loftus EV,
Sandborn W
. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):1-20. PMID: 12122726.
View in:
PubMed
Sandborn W
, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30. PMID: 11832465.
View in:
PubMed
Feagan BG,
Sandborn W
. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev Gastroenterol Disord. 2002; 2 Suppl 2:S9-15. PMID: 12478239.
View in:
PubMed
Dayharsh GA, Loftus EV,
Sandborn W
, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002 Jan; 122(1):72-7. PMID: 11781282.
View in:
PubMed
Loftus EV, Schoenfeld P,
Sandborn W
. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002 Jan; 16(1):51-60. PMID: 11856078.
View in:
PubMed
Mahadevan U,
Sandborn W
. Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):471-6. PMID: 11696284.
View in:
PubMed
Schwartz DA, Pemberton JH,
Sandborn W
. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001 Nov 20; 135(10):906-18. PMID: 11712881.
View in:
PubMed
Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH,
Sandborn W
. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology. 2001 Nov; 121(5):1064-72. PMID: 11677197.
View in:
PubMed
Sandborn W
, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94. PMID: 11677200.
View in:
PubMed
Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM,
Sandborn W
. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001 Nov; 49(5):656-64. PMID: 11600468; PMCID: PMC1728490.
View in:
PubMed
,
PubMed Central
Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ,
Sandborn W
. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001 Nov; 49(5):665-70. PMID: 11600469; PMCID: PMC1728511.
View in:
PubMed
,
PubMed Central
Loftus EV,
Sandborn W
. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology. 2001 Nov; 121(5):1239-42. PMID: 11677218.
View in:
PubMed
Faubion WA, Loftus EV,
Sandborn W
, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr. 2001 Sep; 33(3):296-300. PMID: 11593125.
View in:
PubMed
Tremaine WJ,
Sandborn W
, Loftus EV, Kenan ML, Petterson TM, Zinsmeister AR, Silverstein MD. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol. 2001 Aug; 96(8):2401-6. PMID: 11513181.
View in:
PubMed
Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR,
Sandborn W
. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001 Aug; 121(2):255-60. PMID: 11487534.
View in:
PubMed
Patel AH, Loftus EV, Murray JA, Harmsen WS, Zinsmeister AR,
Sandborn W
. Cigarette smoking and celiac sprue: a case-control study. Am J Gastroenterol. 2001 Aug; 96(8):2388-91. PMID: 11513179.
View in:
PubMed
Sandborn W
, Loftus EV, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001 Aug; 7(3):192-201. PMID: 11515844.
View in:
PubMed
Yang SK, Loftus EV,
Sandborn W
. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis. 2001 Aug; 7(3):260-70. PMID: 11515854.
View in:
PubMed
Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW,
Sandborn W
. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl. 2001 Jun 05; 757(1):1-9. PMID: 11419732.
View in:
PubMed
Decker GA, Loftus EV, Pasha TM, Tremaine WJ,
Sandborn W
. Crohn's disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis. 2001 May; 7(2):113-9. PMID: 11383583.
View in:
PubMed
Sandborn W
. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001 May; 48(5):591-2. PMID: 11302950; PMCID: PMC1728293.
View in:
PubMed
,
PubMed Central
Sandborn W
, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8. PMID: 11313302.
View in:
PubMed
Pardi DS, Loftus EV, Tremaine WJ,
Sandborn W
. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology. 2001 May; 120(6):1483-4. PMID: 11313319.
View in:
PubMed
Coulie B, Camilleri M, Bharucha AE,
Sandborn W
, Burton D. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001 May; 15(5):653-63. PMID: 11328259.
View in:
PubMed
Levy AM, Yamazaki K, Van Keulen VP, Burgart LJ,
Sandborn W
, Phillips SF, Kephart GM, Gleich GJ, Leiferman KM. Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis. Am J Gastroenterol. 2001 May; 96(5):1522-8. PMID: 11374693.
View in:
PubMed
Sandborn W
. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S9-16. PMID: 11380043.
View in:
PubMed
Sands BE, Tremaine WJ,
Sandborn W
, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8. PMID: 11383595.
View in:
PubMed
Sandborn W
. Strategies targeting tumor necrosis factor in Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):170-2. PMID: 11475128.
View in:
PubMed
Sandborn W
. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):201-4. PMID: 11475136.
View in:
PubMed
Hanauer SB,
Sandborn W
. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43. PMID: 11280528.
View in:
PubMed
Ricart E, Panaccione R, Loftus EV, Tremaine WJ,
Sandborn W
. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001 Mar; 96(3):722-9. PMID: 11280541.
View in:
PubMed
Mahadevan U,
Sandborn W
. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis. 2001 Feb; 7(1):38-42. PMID: 11233659.
View in:
PubMed
Sandborn W
, Faubion WA. Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep. 2000 Dec; 2(6):440-5. PMID: 11079044.
View in:
PubMed
Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ,
Sandborn W
. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol. 2000 Dec; 95(12):3463-8. PMID: 11151878.
View in:
PubMed
Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ,
Sandborn W
. Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm Bowel Dis. 2000 Nov; 6(4):286-9. PMID: 11149561.
View in:
PubMed
Limburg PJ, Ahlquist DA,
Sandborn W
, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct; 95(10):2831-7. PMID: 11051356.
View in:
PubMed
Loftus EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR,
Sandborn W
. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000 Sep; 95(9):2308-12. PMID: 11007233.
View in:
PubMed
Sandborn W
. Steroid-dependent Crohn's disease. Can J Gastroenterol. 2000 Sep; 14 Suppl C:17C-22C. PMID: 11023556.
View in:
PubMed
Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, Leteurtre L, Cortot A,
Sandborn W
, Colombel JF, Desreumaux P. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis. 2000 Aug; 6(3):157-64. PMID: 10961587.
View in:
PubMed
Sandborn W
. Therapy for Crohn disease. Curr Opin Gastroenterol. 2000 Jul; 16(4):318-23. PMID: 17031095.
View in:
PubMed
Pardi DS, Tremaine WJ,
Sandborn W
, Loftus EV, Poland GA, Harmsen WS, Zinsmeister AR, Melton LJ. Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol. 2000 Jun; 95(6):1480-5. PMID: 10894583.
View in:
PubMed
Faubion WA,
Sandborn W
. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology. 2000 Mar; 118(3):630-1. PMID: 10702217.
View in:
PubMed
Loftus EV, Silverstein MD,
Sandborn W
, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000 Mar; 46(3):336-43. PMID: 10673294; PMCID: PMC1727835.
View in:
PubMed
,
PubMed Central
Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB,
Sandborn W
, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15. PMID: 10701144.
View in:
PubMed
Sandborn W
, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2):CD000545. PMID: 10796557.
View in:
PubMed
Sandborn W
, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev. 2000; (2):CD001176. PMID: 10796613.
View in:
PubMed
Egan LJ,
Sandborn W
, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999 Dec; 13(12):1597-604. PMID: 10594394.
View in:
PubMed
Ricart E,
Sandborn W
. Infliximab for the treatment of fistulas in patients with Crohn'S disease. Gastroenterology. 1999 Nov; 117(5):1247-8. PMID: 10535892.
View in:
PubMed
Lowry PW, Weaver AL, Tremaine WJ,
Sandborn W
. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999 Nov; 5(4):239-45. PMID: 10579116.
View in:
PubMed
Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG,
Sandborn W
, Lipsky JJ, McKean DJ. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999 Sep 10; 274(37):26448-53. PMID: 10473604.
View in:
PubMed
Sandborn W
, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35. PMID: 10464128.
View in:
PubMed
Ricart E, Panaccione R, Loftus EV, Tremaine WJ,
Sandborn W
. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999 Aug; 117(2):429-32. PMID: 10419926.
View in:
PubMed
Louvet B, Buisine MP, Desreumaux P, Tremaine WJ, Aubert JP, Porchet N, Capron M, Cortot A, Colombel JF,
Sandborn W
. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis. 1999 Aug; 5(3):174-81. PMID: 10453373.
View in:
PubMed
Egan LJ,
Sandborn W
, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999 Aug; 5(3):167-73. PMID: 10453372.
View in:
PubMed
Lowry PW,
Sandborn W
, Lipsky JJ. Mycophenolate mofetil for Crohn's disease? Lancet. 1999 Jul 03; 354(9172):3-4. PMID: 10406354.
View in:
PubMed
Silverstein MD, Loftus EV,
Sandborn W
, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999 Jul; 117(1):49-57. PMID: 10381909.
View in:
PubMed
Panaccione R,
Sandborn W
. The appendix in ulcerative colitis: a not so innocent bystander. Gastroenterology. 1999 Jul; 117(1):272-3. PMID: 10381940.
View in:
PubMed
Lowry PW, Szumlanski CL, Weinshilboum RM,
Sandborn W
. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999 Jun; 116(6):1505-6. PMID: 10391741.
View in:
PubMed
Lowry PW,
Sandborn W
. A comparison of budesonide and mesalamine for active Crohn's disease. Gastroenterology. 1999 May; 116(5):1263. PMID: 10220523.
View in:
PubMed
Sandborn W
. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol. 1999 May; 94(5):1161-71. PMID: 10235187.
View in:
PubMed
Harewood GC, Loftus EV, Tefferi A, Tremaine WJ,
Sandborn W
. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999 May; 5(2):98-103. PMID: 10338378.
View in:
PubMed
Pardi DS, Tremaine WJ,
Sandborn W
, Loftus EV, Poland GA, Melton LJ. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis. 1999 May; 5(2):104-6. PMID: 10338379.
View in:
PubMed
Sandborn W
, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33. PMID: 10338381.
View in:
PubMed
Tremaine WJ,
Sandborn W
. Practice guidelines for inflammatory bowel disease: an instrument for assessment. Mayo Clin Proc. 1999 May; 74(5):495-501. PMID: 10319083.
View in:
PubMed
Panaccione R,
Sandborn W
. Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology. 1999 Apr; 116(4):1001-2; discussion 1002-3. PMID: 10092326.
View in:
PubMed
Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK,
Sandborn W
, Larusso NF, Lindor KD. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 1999 Mar; 44(3):602-7. PMID: 10080157.
View in:
PubMed
Pardi DS, Loftus EV, Tremaine WJ,
Sandborn W
, Alexander GL, Balm RK, Gostout CJ. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc. 1999 Feb; 49(2):153-7. PMID: 9925691.
View in:
PubMed
Sandborn W
, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis. 1999 Feb; 5(1):33-9. PMID: 10028447.
View in:
PubMed
Egan LJ,
Sandborn W
, Mays DC, Tremaine WJ, Fauq AH, Lipsky JJ. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999 Jan; 65(1):29-39. PMID: 9951428.
View in:
PubMed
Muñoz-Juarez M, Pemberton JH,
Sandborn W
, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999 Jan; 42(1):117-20. PMID: 10211531.
View in:
PubMed
Matteson EL, Orces CH, Duffy J, Lipsky JJ, Pike MG,
Sandborn W
. Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis. Arthritis Rheum. 1999 Jan; 42(1):186-7. PMID: 9920030.
View in:
PubMed
Egan LJ,
Sandborn W
. Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov; 115(5):1295-6. PMID: 9797390.
View in:
PubMed
Egan LJ,
Sandborn W
, Mays DC, Tremaine WJ, Lipsky JJ. Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision. Aliment Pharmacol Ther. 1998 Jul; 12(7):679-84. PMID: 9701533.
View in:
PubMed
Sandborn W
, Loftus EV, Ahlquist DA. Association of primary sclerosing cholangitis and colorectal cancer in patients with ulcerative colitis: is it true and does it matter? Gastroenterology. 1998 Jul; 115(1):236-7. PMID: 9649486.
View in:
PubMed
Green JT, Rhodes J, Thomas GA, Evans BK, Feyerabend C, Russell MA,
Sandborn W
. Nicotine carbomer enemas--pharmacokinetics of a revised formulation. Ital J Gastroenterol Hepatol. 1998 Jun; 30(3):260-5. PMID: 9759592.
View in:
PubMed
Loftus EV, Silverstein MD,
Sandborn W
, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998 Jun; 114(6):1161-8. PMID: 9609752.
View in:
PubMed
Egan LJ,
Sandborn W
. Drug therapy of inflammatory bowel disease. Drugs Today (Barc). 1998 May; 34(5):431-46. PMID: 15010706.
View in:
PubMed
Kaditis AG, Perrault J,
Sandborn W
, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr; 26(4):386-92. PMID: 9552133.
View in:
PubMed
Pardi DS, Tremaine WJ,
Sandborn W
, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998 Apr; 93(4):504-14. PMID: 9576439.
View in:
PubMed
Loftus EV, Aguilar HI,
Sandborn W
, Tremaine WJ, Krom RA, Zinsmeister AR, Graziadei IW, Wiesner RH. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998 Mar; 27(3):685-90. PMID: 9500695.
View in:
PubMed
Egan LJ,
Sandborn W
, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998 Mar; 93(3):442-8. PMID: 9517654.
View in:
PubMed
Sandborn W
. Inflammatory bowel disease and hereditary nonpolyposis colorectal cancer: is there a genetic link? Gastroenterology. 1998 Mar; 114(3):608-9. PMID: 9496956.
View in:
PubMed
Nuako KW, Ahlquist DA,
Sandborn W
, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer. 1998 Mar 01; 82(5):822-6. PMID: 9486569.
View in:
PubMed
Sandborn W
. Are short-chain fatty acid enemas effective for left-sided ulcerative colitis? Gastroenterology. 1998 Jan; 114(1):218-9. PMID: 9428236.
View in:
PubMed
Sandborn W
. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998; 225:92-9. PMID: 9515759.
View in:
PubMed
Tremaine WJ,
Sandborn W
, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 1997 Dec; 11(6):1041-6. PMID: 9663827.
View in:
PubMed
Green JT, Thomas GA, Rhodes J, Williams GT, Evans BK, Russell MA, Feyerabend C, Rhodes P,
Sandborn W
. Nicotine enemas for active ulcerative colitis--a pilot study. Aliment Pharmacol Ther. 1997 Oct; 11(5):859-63. PMID: 9354193.
View in:
PubMed
Compton RF,
Sandborn W
, Lawson GM, Sheets AJ, Mays DC, Zins BJ, Tremaine WJ, Lipsky JJ, Mahoney DW, Zinsmeister AR, Offord KP, Hurt RD, Evans BK, Green J. A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Aliment Pharmacol Ther. 1997 Oct; 11(5):865-74. PMID: 9354194.
View in:
PubMed
Sandborn W
. A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology. 1997 Sep; 113(3):1042-3. PMID: 9288004.
View in:
PubMed
Nyam DC, Pemberton JH,
Sandborn W
, Savcenko M. Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 1997 Aug; 40(8):971-2. PMID: 9269816.
View in:
PubMed
Sandborn W
. 6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology. 1997 Aug; 113(2):690-2. PMID: 9247497.
View in:
PubMed
Sandborn W
, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther. 1997 Aug; 11(4):663-71. PMID: 9305473.
View in:
PubMed
Loftus EV, Tremaine WJ, Nelson RA, Shoemaker JD,
Sandborn W
, Phillips SF, Hasan Y. Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc. 1997 Jul; 72(7):616-20. PMID: 9212762.
View in:
PubMed
Sandborn W
. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997 May; 92(5):876-9. PMID: 9149205.
View in:
PubMed
Zins BJ,
Sandborn W
, Mays DC, Lawson GM, McKinney JA, Tremaine WJ, Mahoney DW, Zinsmeister AR, Hurt RD, Offord KP, Lipsky JJ. Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. J Clin Pharmacol. 1997 May; 37(5):426-36. PMID: 9156375.
View in:
PubMed
Sandborn W
, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997 Mar 01; 126(5):364-71. PMID: 9054280.
View in:
PubMed
Green JT, Thomas GA, Rhodes J, Evans BK, Russell MA, Feyerabend C, Fuller GS, Newcombe RG,
Sandborn W
. Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. Clin Pharmacol Ther. 1997 Mar; 61(3):340-8. PMID: 9084459.
View in:
PubMed
Sandborn W
. Erythropoietin for inflammatory bowel disease anemia. Gastroenterology. 1997 Feb; 112(2):660-1. PMID: 9024321.
View in:
PubMed
Levy AM, Gleich GJ,
Sandborn W
, Tremaine WJ, Steiner BL, Phillips SF. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc. 1997 Feb; 72(2):117-23. PMID: 9033543.
View in:
PubMed
Zins BJ,
Sandborn W
, McKinney JA, Mays DC, van Os EC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. J Clin Pharmacol. 1997 Jan; 37(1):38-46. PMID: 9048271.
View in:
PubMed
Compton RF,
Sandborn W
, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA, Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter AL, Plevy SE, Cominelli F, Targan SR, Rotter JI. A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology. 1997 Jan; 112(1):241-9. PMID: 8978365.
View in:
PubMed
Li X, Hamdy R,
Sandborn W
, Chi D, Dyer A. Long-term effects of antidepressants on balance, equilibrium, and postural reflexes. Psychiatry Res. 1996 Jul 31; 63(2-3):191-6. PMID: 8878315.
View in:
PubMed
Van Os EC, Zins BJ,
Sandborn W
, Mays DC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 1996 Jul; 39(1):63-8. PMID: 8881811; PMCID: PMC1383233.
View in:
PubMed
,
PubMed Central
Loftus EV,
Sandborn W
, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 1996 May; 110(5):1496-502. PMID: 8613055.
View in:
PubMed
Sandborn W
, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996 May; 71(5):431-6. PMID: 8628021.
View in:
PubMed
Van Os EC, McKinney JA, Zins BJ, Mays DC, Schriver ZH,
Sandborn W
, Lipsky JJ. Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Apr 26; 679(1-2):147-54. PMID: 8998554.
View in:
PubMed
Sandborn W
. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996 Mar; 91(3):423-33. PMID: 8633486.
View in:
PubMed
Penna C, Dozois R, Tremaine W,
Sandborn W
, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996 Feb; 38(2):234-9. PMID: 8801203; PMCID: PMC1383029.
View in:
PubMed
,
PubMed Central
Loftus EV,
Sandborn W
, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton LJ. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996 Feb; 110(2):432-40. PMID: 8566590.
View in:
PubMed
Sandborn W
, Tremaine WJ, Lawson GM. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol. 1996 Jan; 91(1):37-43. PMID: 8561141.
View in:
PubMed
Egan LJ,
Sandborn W
. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc. 1996 Jan; 71(1):69-80. PMID: 8538238.
View in:
PubMed
Zins BJ,
Sandborn W
, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH, Dozois RR. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 Dec; 90(12):2177-81. PMID: 8540511.
View in:
PubMed
Sandborn W
, Van O EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995 Dec; 109(6):1808-17. PMID: 7498645.
View in:
PubMed
Sandborn W
. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology. 1995 Sep; 109(3):1001-3. PMID: 7657085.
View in:
PubMed
Zins BJ,
Sandborn W
, Tremaine WJ. Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. Am J Gastroenterol. 1995 Sep; 90(9):1394-400. PMID: 7661156.
View in:
PubMed
Sandborn W
, Tremaine WJ, Batts KP, Pemberton JH, Rossi SS, Hofmann AF, Gores GJ, Phillips SF. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci. 1995 Jul; 40(7):1474-83. PMID: 7628271.
View in:
PubMed
Sandborn W
, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995 May; 90(5):740-7. PMID: 7733080.
View in:
PubMed
Loftus EV,
Sandborn W
. Drug therapy for inflammatory bowel disease. Contemp Intern Med. 1995 Apr; 7(4):21-34. PMID: 10150344.
View in:
PubMed
Sandborn W
, Lawson GM, Cody TJ, Porayko MK, Hay JE, Gores GJ, Steers JL, Krom RA, Wiesner RH. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995 Jan; 21(1):70-6. PMID: 7528712.
View in:
PubMed
Sandborn W
. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994 Dec; 107(6):1856-60. PMID: 7958702.
View in:
PubMed
Sandborn W
, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994 Jun; 106(6):1429-35. PMID: 8194687.
View in:
PubMed
Sandborn W
, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994 May; 69(5):409-15. PMID: 8170189.
View in:
PubMed
Sandborn W
, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr; 19(4):925-32. PMID: 8138267.
View in:
PubMed
Sandborn W
, Gross JB, Larson DE, Phillips JK, Lindor KD. High-volume postobstructive choleresis after transhepatic external biliary drainage resolves with conversion to internal drainage. J Clin Gastroenterol. 1993 Jul; 17(1):42-5. PMID: 8409297.
View in:
PubMed
Sandborn W
, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993 May; 88(5):640-5. PMID: 8480724.
View in:
PubMed
Sandborn W
, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 1993 Feb; 34(2):242-6. PMID: 8432481; PMCID: PMC1373978.
View in:
PubMed
,
PubMed Central
Sandborn W
, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992 Oct; 67(10):981-90. PMID: 1434859.
View in:
PubMed
Sandborn W
, Goldman DH, Lawson GM, Perrault J. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1992 Aug; 15(2):125-9. PMID: 1357126.
View in:
PubMed
Sandborn W
, Lawson GM, Krom RA, Wiesner RH. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology. 1992 Jun; 15(6):1086-91. PMID: 1592348.
View in:
PubMed
Sandborn W
, Strong RM, Forland SC, Chase RE, Cutler RE. The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. J Clin Pharmacol. 1991 Jan; 31(1):76-80. PMID: 2045532.
View in:
PubMed
Sandborn W
, Forland SC, Cutler RE, Strong RM. Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. J Clin Pharmacol. 1990 Jun; 30(6):568-71. PMID: 2355107.
View in:
PubMed
View timeline visualization
Year
Publications
1990
1
1991
1
1992
3
1993
3
1994
4
1995
8
1996
10
1997
16
1998
14
1999
25
2000
14
2001
27
2002
19
2003
18
2004
22
2005
19
2006
29
2007
33
2008
26
2009
27
2010
34
2011
34
2012
31
2013
41
2014
40
2015
49
2016
41
2017
29
2018
4
William's Networks
Concepts
Derived automatically from this person's publications.
Antibodies, Monoclonal
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Agents
Colitis, Ulcerative
See all (833) concept(s)
_
Co-Authors
People in Profiles who have published with this person.
Chang, John
Dulai, Parambir
Boland, Brigid
Vande Casteele, Niels
Singh, Siddharth
See all (33) people
_
Similar People
People who share similar concepts with this person.
Kavanaugh, Arthur
Dulai, Parambir
Kurzrock, Razelle
Vande Casteele, Niels
Singh, Siddharth
See all (60) people
_
Same Department
Brigger, Matthew
Parker, Kathryn
Sandler, Bryan
Sood, Divya
Tung, Howard
Search Department
Physical Neighbors
People whose addresses are nearby this person.
Corey-Bloom, Jody
U, Hoi
Romero, Jairo
Kalmaz, Denise
Vande Casteele, Niels
_